[Research progress on rhinitis medicamentosa].

Rhinitis medicamentosa (RM) refers to nonallergic inflammation in the nasal mucosa which is caused by the abuse of nasal decongestant and it often occurs in patients with allergic/nonallergic rhinitis along with nasal congestion. RM is characterized by nasal congestion based on long-term use of nasal decongestant, without rhinorrhoea or sneezing. The signs of RM include nasal swelling, thickening, loss of elasticity, and loss of sensitivity to the decongestant. The histological changes of RM are loss of nasal mucosa cilia, squamous epithelium metaplasia, edema of epithelium cell, hyperplasia of goblet cell, increased expression of epidermal growth factor receptor and infiltration of inflammatory cells, etc. There is no precise diagnosis standard for RM, making it even harder for its objective diagnosis. Patients with RM should immediately stop using nasal decongestant, in stead of using nasal glucocorticoid spray for the recovery of the nasal mucosa's function.

[Research progress of animal model of allergic rhinitis].

The animal model of allergic rhinitis is ciritical for the study of this disease.Guinea pig,mouse,rat,rabbit and other animals can be selected.Allergen includes ovalbumin,pollen,dust mites,available fungi,roundworm and schistosome antigen.Aluminum hydroxide adjuvant is most commonly used.To enhance the sensitivity,nasal drops can be selected,inhalation and multi-point subcutaneous injection is optional.Nasal itching,sneezing,clear nasal discharge ,or specific histopathological and immunological results can indicate the success of modeling.Immunological test is the most important standard to determine whether the model is successful or not.This review summarizes the recent advances in the study of animal models of allergic rhinitis.

[Comparison study of subcutaneous immunotherapy and sublingual immunotherapy in patients with allergic rhinitis].

Objective: To observe the compliance, efficacy and safety of subcutaneous immunotherapy(SLIT) and sublingual immunotherapy(SCIT) in patients with allergic rhinitis(AR).Method:One hundred and fifteen patients sensitized to house dust mites were recruited in this study. The standardized extract of house dust mites was used for SLIT in 64 cases, and the standardized extract of dual house dust mites was used for SCIT in the other 51 cases. The compliance, nasal symptom scores, the medication scores, the quality of life and the adverse reaction were evaluated before and 2 years after immunotherapy. SPSS 19.0 was used for data analysis. Result:Forty patients out of 64 completed the 2 years-SLIT, and the compliance rate was 62.50%. Forty three patients out of 51 completed the 2 years-SCIT and the compliance rate was 84.31%.The compliance rate of SLIT was significantly lower than that of SCIT(P <0.05). The nasal symptom scores, the anti-allergic medication, the scores in quality of life decreased significantly after receiving SLIT or SCIT for 2 years（P <0.05）. However, the changed values of scores between the two groups had no significant differences（P >0.05）. There was no moderate or severe adverse reactions occurred in SLIT group but a total of 6 moderate or severe adverse reactions occurred in SCIT group.Conclusion:SLIT has same effect compared with SCIT with a lower compliance rate but a significantly higher safety.